Literature DB >> 11992553

Body mass index in relation to ovarian cancer: a multi-centre nested case-control study.

Annekatrin Lukanova1, Paolo Toniolo, Eva Lundin, Andrea Micheli, Arslan Akhmedkhanov, Paola Muti, Anne Zeleniuch-Jacquotte, Carine Biessy, Per Lenner, Vittorio Krogh, Franco Berrino, Goran Hallmans, Elio Riboli, Rudolf Kaaks.   

Abstract

The incidence of ovarian cancer is up to 10 times higher in Western countries than in rural Asia and Africa. One common consequence of a Western lifestyle is the development of excessive body weight and obesity. A multi-centre prospective study was conducted to investigate the association between body mass index (BMI) and ovarian cancer risk. A case-control study was nested within 3 prospective cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). Information on anthropometry, demographic characteristics, medical history and lifestyle was obtained at the time of subjects' recruitment in each cohort. Women diagnosed with primary, invasive epithelial ovarian cancer from the 3 cohorts (n = 122) diagnosed 12 months or later after recruitment into the respective cohort served as case subjects. For each case subject, 2 control subjects that matched the case subject on cohort, menopausal status, age and date of recruitment were randomly identified. Data were analyzed by conditional logistic regression. There was an inverse association between BMI and ovarian cancer risk. For increasing quartiles of BMI above the lowest, the ORs were 0.62 (0.32-1.21), 0.59 (0.30-1.17) and 0.46 (0.23-0.92), p = 0.03. Analyses limited to women diagnosed 3 or more years after recruitment into the cohorts did not alter these findings. When obese women (BMI > 30) were compared to lean women (BMI < or = 23), the inverse association became stronger, with an OR of 0.38 (0.17-0.85), p < 0.02. There was some evidence of direct association of ovarian cancer with height, which was limited to cancers diagnosed before age 55. Our data suggest that increasing body weight may confer a protection against ovarian cancer. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11992553     DOI: 10.1002/ijc.10374

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.

Authors:  Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

2.  Body size in early life and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.

Authors:  H J Baer; S E Hankinson; S S Tworoger
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640

3.  Reliability of follicle-stimulating hormone measurements in serum.

Authors:  Alan A Arslan; Anne Zeleniuch-Jacquotte; Annekatrin Lukanova; Sabina Rinaldi; Rudolf Kaaks; Paolo Toniolo
Journal:  Reprod Biol Endocrinol       Date:  2003-06-18       Impact factor: 5.211

4.  Circulating soluble Fas levels and risk of ovarian cancer.

Authors:  Arslan Akhmedkhanov; Eva Lundin; Seth Guller; Annekatrin Lukanova; Andrea Micheli; Yuehong Ma; Yelena Afanasyeva; Anne Zeleniuch-Jacquotte; Vittorio Krogh; Per Lenner; Paola Muti; Sabina Rinaldi; Rudolf Kaaks; Franco Berrino; Göran Hallmans; Paolo Toniolo
Journal:  BMC Cancer       Date:  2003-12-22       Impact factor: 4.430

5.  DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk.

Authors:  Dominique Bernard-Gallon; Rémy Bosviel; Laetitia Delort; Luc Fontana; Alain Chamoux; Nadège Rabiau; Fabrice Kwiatkowski; Nasséra Chalabi; Samir Satih; Yves-Jean Bignon
Journal:  Mol Cancer       Date:  2008-05-02       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.